|
1
|
International Agency for Research on
Cancer, . Colorectal cancer. Source: Globocan 2018. The Global
Cancer Observatory. 2019.
|
|
2
|
Cook AD, Single R and McCahill LE:
Surgical resection of primary tumors in patients who present with
stage IV colorectal cancer: An analysis of surveillance,
epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol.
12:637–645. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Gestel YR, de Hingh IH, van Herk-Sukel
MP, van Erning FN, Beerepoot LV, Wijsman JH, Slooter GD, Rutten HJ,
Creemers GJ and Lemmens VE: Patterns of metachronous metastases
after curative treatment of colorectal cancer. Cancer Epidemiol.
38:448–454. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold D; ESMO Guidelines Working Group, : Metastatic
colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii1–9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie YH, Chen YX and Fang JY: Comprehensive
review of targeted therapy for colorectal cancer. Signal Transduct
Target Ther. 5:222020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY,
Xue K, Li J and Chen Q: Predictive and prognostic value of KRAS
mutations in metastatic colorectal cancer patients treated with
cetuximab: a meta-analysis of 22 studies. Eur J Cancer.
46:2781–2787. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Benson AB III, Venook AP, Bekaii-Saab T,
Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ,
Fuchs CS, et al: Colon cancer, version 3. 2014. J Natl Compr Canc
Netw. 12:1028–1059. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Allegra CJ, Rumble RB and Schilsky RL:
Extended RAS gene mutation testing in metastatic colorectal
carcinoma to predict response to anti epidermal growth factor
receptor monoclonal antibody therapy: American society of clinical
oncology provisional clinical opinion update 2015 summary. J Oncol
Pract. 12:180–181. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bokemeyer C, Köhne CH, Ciardiello F, Lenz
HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH
and Tejpar S: FOLFOX4 plus cetuximab treatment and RAS mutations in
colorectal cancer. Eur J Cancer. 51:1243–1252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peeters M, Oliner KS, Price TJ, Cervantes
A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, et
al: Analysis of KRAS/NRAS mutations in a phase III study of
panitumumab with FOLFIRI compared with FOLFIRI alone as second-line
treatment for metastatic colorectal cancer. Clin Cancer Res.
21:5469–5479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Van Cutsem E, Lenz HJ, Köhne CH, Heinemann
V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken
JH and Ciardiello F: Fluorouracil, leucovorin, and irinotecan plus
cetuximab treatment and RAS mutations in colorectal cancer. J Clin
Oncol. 33:692–700. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jamal-Hanjani M, Quezada SA, Larkin J and
Swanton C: Translational implications of tumor heterogeneity. Clin
Cancer Res. 21:1258–1266. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gormally E, Caboux E, Vineis P and Hainaut
P: Circulating free DNA in plasma or serum as biomarker of
carcinogenesis: Practical aspects and biological significance.
Mutat Res. 635:105–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Diehl F, Schmidt K, Durkee KH, Moore KJ,
Goodman SN, Shuber AP, Kinzler KW and Vogelstein B: Analysis of
mutations in DNA isolated from plasma and stool of colorectal
cancer patients. Gastroenterology. 135:489–498. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hodgson DR, Wellings R, Orr MC McCormack
R, Malone M, Board RE and Cantarini MV: Circulating tumour-derived
predictive biomarkers in oncology. Drug Discov Today. 15:98–101.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jung K, Fleischhacker M and Rabien A:
Cell-free DNA in the blood as a solid tumor biomarker-a critical
appraisal of the literature. Clin Chim Acta. 411:1611–1624. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schwarzenbach H, Stoehlmacher J, Pantel K
and Goekkurt E: Detection and monitoring of cell-free DNA in blood
of patients with colorectal cancer. Ann N Y Acad Sci. 1137:190–196.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De Mattos-Arruda L, Olmos D and Tabernero
J: Prognostic and predictive roles for circulating biomarkers in
gastrointestinal cancer. Future Oncol. 7:1385–1397. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pantel K and Alix-Panabières C: Real-time
liquid biopsy in cancer patients: Fact or fiction? Cancer Res.
73:6384–6388. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haber DA and Velculescu VE: Blood-based
analyses of cancer: Circulating tumor cells and circulating tumor
DNA. Cancer Discov. 4:650–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma M, Zhu H, Zhang C, Sun X, Gao X and
Chen G: ‘Liquid biopsy’-ctDNA detection with great potential and
challenges. Ann Transl Med. 3:2352015.PubMed/NCBI
|
|
25
|
Chen CC, Er TK, Liu YY, Hwang JK, Barrio
MJ, Rodrigo M, Garcia-Toro E and Herreros-Villanueva M:
Computational analysis of KRAS mutations: Implications for
different effects on the KRAS p.G12D and p.G13D mutations. PLoS
One. 8:e557932013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
El Messaoudi S, Mouliere F, Du Manoir S,
Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau
F, Theillet C, et al: Circulating DNA as a strong multimarker
prognostic tool for metastatic colorectal cancer patient management
care. Clin Cancer Res. 22:3067–3077. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Basnet S, Zhang ZY, Liao WQ, Li SH, Li PS
and Ge HY: The prognostic value of circulating cell-free DNA in
colorectal cancer: A meta-analysis. J Cancer. 7:1105–1113. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
TNM Classification of Malignant Tumours, ;
Sobin LH, Gospodarowicz MK and Wittekind Ch: 7th edition.
Wiley-Blackwell; 2011
|
|
30
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Spindler KL, Appelt AL, Pallisgaard N,
Andersen RF, Brandslund I and Jakobsen A: Cell-free DNA in healthy
individuals, noncancerous disease and strong prognostic value in
colorectal cancer. Int J Cancer. 135:2984–2991. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Germano G, Mauri G, Siravegna G, Dive C,
Pierce J, Di Nicolantonio F, D'Incalci M, Bardelli A, Siena S and
Sartore-Bianchi A: Parallel evaluation of circulating tumor DNA and
circulating tumor cells in metastatic colorectal cancer. Clin
Colorectal Cancer. 17:80–83. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schmiegel W, Scott RJ, Dooley S, Lewis W,
Meldrum CJ, Pockney P, Draganic B, Smith S, Hewitt C, Philimore H,
et al: Blood-based detection of RAS mutations to guide anti-EGFR
therapy in colorectal cancer patients: Concordance of results from
circulating tumor DNA and tissue-based RAS testing. Mol Oncol.
11:208–219. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
García-Foncillas J, Tabernero J, Élez E,
Aranda E, Benavides M, Camps C, Jantus-Lewintre E, López R,
Muinelo-Romay L, Montagut C, et al: Prospective multicenter
real-world RAS mutation comparison between OncoBEAM-based liquid
biopsy and tissue analysis in metastatic colorectal cancer. Br J
Cancer. 119:1464–1470. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bachet JB, Bouché O, Taieb J, Dubreuil O,
Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, et
al: RAS mutation analysis in circulating tumor DNA from patients
with metastatic colorectal cancer: The AGEO RASANC prospective
multicenter study. Ann Oncol. 29:1211–1219. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lastraioli E, Lavacchi D, Palmieri VE,
Castiglione F, Messerini L, Di Costanzo F and Antonuzzo L:
Evaluation of RAS mutational status through BEAMing assay to
monitor disease progression of metastatic colorectal cancer: A case
report. Anticancer Drugs. 31:979–982. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bando H, Kagawa Y, Kato T, Akagi K, Denda
T, Nishina T, Komatsu Y, Oki E, Kudo T, Kumamoto H, et al: A
multicentre, prospective study of plasma circulating tumour DNA
test for detecting RAS mutation in patients with metastatic
colorectal cancer. Br J Cancer. 120:982–986. 2019. View Article : Google Scholar : PubMed/NCBI
|
